Shows
AfterShock: Leadership for the 5th Industrial Revolution with Caroline StokesEp. 8: Philosopher Samuel Loncar explores the hidden values shaping technology and leadershipWhat does it mean to flourish in an age defined by AI, disruption, and uncertainty?In this AfterShock episode, philosopher and writer Samuel Loncar explores the cultural forces and hidden assumptions that shape not just technology, but the way we lead. As founding editor of the Marginalia Review of Books and a consultant to scientists and institutions worldwide, Loncar reveals how narratives of progress, salvation, and transcendence quietly drive the boldest ambitions in Silicon Valley — and why they matter for every leader today.From the “Manhattan Project” mindset in AI lab...
2025-08-251h 19
Biotech HangoutEpisode 147 - July 11, 2025On this week’s episode, Eric Schmidt, Brad Loncar, Tim Opler and Tess Cameron kick off with a discussion on the surgein biotech M&A, with 2025 almost matching 2024’s deal count and surpassing it in value ($40B YTD vs $30B), highlighting recent deals like Merck’s acquisition of Verona and AbbVie’s purchase of Capstan. The group debateswhether this signals a true “M&A wave,” noting pharma’s $150 billion of LOE approaching and reduced macro uncertainty could be driving deal flow. They alsonote a current competitive dynamic around commercial-stage assets. Shifting to policy, Trump’s “Big Beautiful Bill” introduces key IRA exemptions f...
2025-07-2259 minBiotech HangoutEpisode 144 - June 6, 2025On this week’s episode, Brad Loncar, Eric Schmidt, and Sam Fazeli kick off with a look at Sanofi’s $9 billion acquisition of Blueprint Medicines, highlighting the move as a mature, strategic bet for Sanofi and a positive sign for investment in biotech. On the data front, the group highlights the Phase 3 HARMONi trial from Summit and Akeso in non-small cell lung cancer, which is the first to include both U.S. and Chinese patients in a head-to-head comparison with Keytruda. Vera Therapeutics’ positive Phase 3 data in IgA nephropathy was also discussed. The conversation shifts to ASCO 2025, spotlighting early-stage data in...
2025-06-1058 min
Becoming HumanHow a Celebrity Philosopher Changed History & Why He Was Forgotten: Emily Herring on Henri BergsonHow did the most famous philosopher of his time, a darling of the Parisian salons and an internationally renowned philosopher of science, disappear from memory? Dr. Emily Herring, author of Herald of a Restless World: How Henri Bergson Brought Philosophy to the People, explains the brilliant insights and legacy of Bergson in this wide-ranging Becoming Human Conversation with Samuel Loncar. The French philosopher Henri Bergson wrote brilliantly about the brain, biology, memory, time, and creativity, exploring the relationship of science, philosophy, and mysticism, yet he has been largely neglected and forgotten. As Herring explores why...
2025-05-121h 08
People SoupEmbracing Intellectual Humility with Tom LoncarHi there and a very warm welcome to Season 6 Episode 23 of People Soup, it's Ross McIntosh here. P-Soupers - In this episode it's the second part of my chat with Tom Loncar who is an accredited coach, mentor and contributing writer on leadership to a variety of business and professional magazines, including The Psychologist, the official magazine of the British Psychological Society) Tom's people soup ingredients are curiosity, enthusiasm, and learning with a side order of building connections! Tom discusses the concept of intellectual humility, emphasizing the importance of recognizing our incomplete knowledge and welcoming t...
2025-04-3036 min
People SoupCoaching, Creativity and The Cramps with Tom LoncarHi there and a very warm welcome to Season 6 Episode 22 of People Soup, it's Ross McIntosh here. P-Soupers - In this episode I chat with Tom Loncar who is an accredited coach and mentor with a background that spans the corporate sector, the public sector and roles as an economist and consultant. He is also a contributing writer on leadership to leading business and professional magazines including the Australian Financial Review, BOSS Magazine and The Psychologist, official magazine of the British Psychological Society. Tom's People Soup ingredients are curiosity, enthusiasm, and learning with a side order of b...
2025-04-2329 minBiotech HangoutEpisode 138 - April 11, 2025On this week’s episode, Chris Garabedian, Brad Loncar, Eric Schmidt, Paul Matteis, and Tess Cameron begin by recapping the markets, highlighting the rise in bond yields. The discussion then transitions to the efficiency of the FDA, noting its current overextension. Next, the group addresses an open letter from biotech executives and investors to Senator Bill Cassidy, highlighting the dismissal of key employees important to FDA review processes. Park Marks’ dismissal is also revisited, along with the impending threat of pharmaceutical tariffs. Wrapping up the discussion on the FDA, its initiative to replace animal testing is overviewed. The conversation shif...
2025-04-181h 00Biotech HangoutEpisode 137 - April 4, 2025On this week’s episode, Eric Schmidt, Brad Loncar, Yaron Werber, Paul Matteis, and Nina Kjellson discuss impact of tariffs on biopharma relative to other sectors, FDA updates and bright spots, data, and fundraising. The episode opens with a conversation on tariffs and the upheaval and shifts at the FDA, including the departure of Peter Marks, former director of the FDA’s Center for Biologics Evaluation and Research, which has the group concerned over loss of institutional memory, history, and the ability to meet deadlines. The conversation shifts to the measles outbreak, noting concerns about public health and future regula...
2025-04-181h 00
Becoming HumanThe Age of Spiritual Awakening: Rabbi Simon Jacobson in Conversation | ExplorationsAccording to Rabbi Simon Jacobson of The Meaningful Life Center, technology is catalyzing a spiritual awakening, making spiritual knowledge the “key commodity of the future.” Rabbi Jacobson is a best-selling author of Towards a More Meaningful Life and reaches hundreds of thousands daily through his YouTube channel. In this far-reaching Becoming Human Conversation, we explore anxiety and “healthy angst,” why religion is declining and spirituality is growing, what the spirit is, why the “messianic age” is about the elevation of human consciousness, and how he would respond if he was representing humanity to a delegation of ethically...
2025-04-1406 min
Becoming HumanHow AGI and Superintelligence Enhance Consciousness | Apocalypse, A Philosophy of Angels, Ep. 7Has AGI (Artificial General Intelligence) already arrived? As the race for Superintelligent machines changes the world, how can humans prepare to thrive? Ancient spiritual traditions reveal surprising insights into how philosophy as a spiritual technology can teach us where AI is heading, and what to do about it. Instructor: Dr. Samuel Loncar | Yale University
2025-03-1424 minBiotech HangoutEpisode 132 - February 21, 2025On this episode of Biotech Hangout hosts Brad Loncar, Eric Schmidt, Tess Cameron, Luba Greenwood, and Tim Opler, along with special guest Adam Feuerstein, kick off with a discussion on ‘zombie’ biotech companies – those trading below their cash value – and whether they can be revived or should return capital to investors. The conversation then turns to Stoke’s collaboration agreement with Biogen, Solid Biosciences’ promising gene therapy data for Duchenne muscular dystrophy, and industry concerns over biotech fundraising practices. Other key topics include Bluebird Bios take-private acquisition, SpringWorks’ potential buyout by Merck KGaA, and updates in the obesity space, including the...
2025-02-2759 min
Becoming HumanEducation for the AI Age: Why Can't People Read and Does it Matter? | ExplorationsHow do we reimagine education for a world of AI? What skills do people need, and why? How can philosophy as a way of life create a shared vision of human flourishing? Instructor: Samuel Loncar, Ph.D. | Yale University
2025-02-2724 minBiotech HangoutEpisode 129 - January 31, 2025On this week’s episode, Brad Loncar, Chris Garabedian, Eric Schmidt, Paul Matteis and Sam Fazeli kick off with an open mic session on the potential impact of the RFK Jr. hearings and the Trump administration's policies on the biotech industry. The conversation turns to a “unicorn day” with IPOs for Metsara, Maze, Odyssey and Sionna Therapeutics. The group also discusses the approval of Vertex’s journavx and the potential for it to be a blockbuster drug. Akero, Sarepta and Cargo also announced data this week and the hosts summarized the market reactions. Other topics covered include Merck’s buyback an...
2025-02-231h 00Biotech HangoutEpisode 126 - January 10, 2025On this week’s episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Sto...
2025-02-2358 minBiotech HangoutEpisode 125 - December 20, 2024On this week’s episode, Brad Loncar, Daphne Zohar, Josh Schimmer, Yaron Werber and Michael Preminger kick off the show with Vertex’s much anticipated Phase 2 study results, highlighting the modest treatment effect and high placebo response. The group also comments on overly positive spin on data and the importance of credibility in interpreting data. The conversation turns to Novo Nordisk’s weight loss data and the market’s negative reaction with stock down 20%. The group also discusses Roche’s termination of its hemophilia gene therapy program, and Teva's TL1A data showing promise in inflammatory bowel disease. Turning to market...
2025-02-2359 minBiotech HangoutEpisode 121 - November 15, 2024On this episode, Brad Loncar, Sam Fazeli, Tess Cameron, Nina Kjellson and Michal Preminger kick off the show sharing perspectives on Trump’s selection of Robert F. Kennedy Jr as secretary of the U.S. Department of Health and Human Services. The hosts shift to Abbvie’s disappointing Phase 2 trials and a broader discussion on why M&A can be tough. The group also discussed the recent flood of licensing and new companies based on China assets, including some of the players and approaches. The hosts also discuss Halozyme's takeover proposal of Evotec, the VEGF/PD-1 frenzy, J&J hits...
2025-02-231h 00
Becoming HumanCan We Change Our Fate? An Existential Vision for Immortality | ExplorationsFate is the power of the unchosen to determine your life. It is real and we all know it, or we would never be frustrated. The key question is: can we overcome our fate? Is fate compatible with freedom? An existential strategy is the only way to overcome the power of fate and avoid being a pawn of your environment and history. To conquer fate, we must pursue a scientific understanding of reality, and overcome our limitations. The result is a life ready for immortality. Long-term planning in short-sighted Western corporations is 10 years, 30 at most. China has...
2025-02-2136 minBiotech HangoutJanuary 10, 2025On this week’s episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Sto...
2025-02-0758 min
Becoming HumanWill Superintelligence Complete Science? The Future of PhysicsWhat happens when AGI, Artificial General Intelligence, appears and solves all the problems in science? Can we know the future of science? Thomas Kuhn's The Structure of Scientific Revolutions, Chapter 6, suggests we can predict future scientific developments based on a deep understanding of the current anomalies in our ideas. Our philosophical ideas of nature can provide an orientation towards future research, giving us a window into the future. What do we see if we look? Series: Notes on Kuhn's The Structure of Scientific Revolutions, Ep. 7. Instructor: Samuel Loncar, Ph.D | Yale University
2025-02-0329 min
Becoming HumanCan a New Scientific Revolution Explain Consciousness? | Apocalypse: A Philosophy of Angels, Ep. 6Three Theses about the Future of Science We are living through the greatest scientific revolution in over two millennia. 2. A new revolution in biology connects to the AI revolution, and a scientific theory of consciousness may finally be on the horizon as a result. 3. Real philosophy should be scientific and thus able to make predictions. I make three predictions about the next 10 years of science. Together, these point towards a new theory of consciousness that is philosophically profound, scientifically productive, and existentially significant. Apocalypse: A Philosophy of Angels, Ep.6 Ins...
2025-01-311h 08
Becoming HumanCan We Have Infinite Energy? Can the Tao Make Us Immortal? | Tao Te Ching, Ep. 4The Tao Te Ching teaches that the Way offers infinite utility, seeming to promise unending energy and life. Is this possible and what, scientifically, might it mean? Exploring Chapter 4 of the Tao Te Ching, I show how the human senses point towards hidden paths of refinement and mysteriously deep sources of energy and insight, all found within the physical body. Tao Te Ching, Ep. 4 Instructor: Samuel Loncar, Ph.D. | Yale University
2025-01-2445 min
Becoming HumanDo Humans Really Exist? Do We Live in a Simulation? | ExplorationsThe simulation theory is all around us, putting somehow the meaning of our very existence into question. Do we really exist? What does it mean that we question our own existence? A true philosophy of existence must answer these questions, and explain why we ask them, guiding us towards a more conscious, free, and scientific way of life. This is the purpose of the Becoming Human Project: to realize human Existence. Instructor: Dr. Samuel Loncar | Yale University
2025-01-2114 min
Becoming HumanCan Philosophy Make You Powerful? A Vision of Human Enhancement, Philosophy of Angels Ep. 5If you can get one thing you want, what is the one thing that will give you everything else? Is it power, wealth, or wisdom? Philosophy as a spiritual way of life teaches us how to develop our human potential, leading to a radical vision of human enhancement. The idea of number is the first step to understanding the coded Messengers of spiritual traditions and how they guide us to a more scientific and positive way of life. 🙏This video is dedicated to Namagiri with gratitude. Instructor: Dr. Samuel Loncar...
2025-01-171h 04
Becoming HumanHow Do We Know What is Good?, Tao Series Ep. 3We all want to do good, but we rarely think about how we can know what the good is. In this video, I discuss Verse 8 of the Tao and its highly logical and practical insights into what is good in any situation and how we can know that we are doing what is good for ourselves and others. SERIES: Tao Te Ching Instructor: Samuel Loncar, Ph.D. | Yale University Episode 3, Tao Te Ching
2025-01-1020 minBiotech HangoutEpisode 117On this week’s episode of Biotech Hangout, hosts Daphne
Zohar, Josh Schimmer, Brad Loncar, John Maraganore, Paul Matteis, Mike Yee and Tess Cameron open up with market commentary and how derivatives, debates and
dynamics are impacting stocks including Scholar Rock, Biohaven, Roche and Regeneron. The group also highlights CeriBell, which is the first medtech IPO
in years. The hosts turn to neuro sentiment with a look at Lundbeck’s acquisition of Longboard at an approximate value of $2.5 billion net of cash. The conversation turns to the idea of competitors benefiting from M&A and data, with this week’s exam...
2024-10-3058 minBiotech HangoutEpisode 115On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Sam Fazeli and Tess Cameron kick off the show digging into some macro trends and the potential of an incoming M&A wave. The conversation then turns to a range of topics related to China, including the impact of the stimulus, recent innovation, and the latest obesity assets & China-sourced drugs. The hosts also discuss the updates coming out of Roche’s business day, including
the company’s acquisition of a CDK inhibitor from China’s Regor. On the data front, the hosts discuss Poseida and Roche’s myeloma data and J...
2024-10-3059 minBiotech HangoutEpisode 14
On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Chris Garabedian, John Maraganore and Sam Fazeli kick off the show sharing perspectives on the markets and its effects on the growing queue of biotech IPOs, particularly following the influx of large private deals over the past few months. As the founding CEO of Alnylam, John provides his thoughts on the Helios-B full study data presentation at the ESC Congress while the broader group weighs in on the competitive implications of the data. The hosts also discuss Recursion, which shared some mixed data this week on it...
2024-09-251h 00
The Sales Circle | With Rob SpenceInterview With Stefan Loncar, Loncom ConsultingEpisode 13 | The Sales Circle | Interview With Stefan Loncar, Loncom ConsultingWelcome to The Sales Circle—the ultimate podcast for sales professionals and anyone eager to master the art of selling! Hosted by internationally renowned sales trainer Rob Spence, our weekly episodes are packed with actionable insights, practical strategies, and motivational stories to help you with your sales game.Get ready for an eye-opening conversation in our latest episode as host Rob Spence engages with Stefan Loncar, the visionary owner of Loncom Consulting. Join us as we explore a unique approach to...
2024-09-1939 minBiotech HangoutEpisode 113On this week’s Biotech Hangout, hosts Brad Loncar, Tim Opler, Josh Schimmer and Sam Fazeli assess the recent macro trends, including the current state of the US economy and some good news for biotech. The group also discussed the big reveal this week on Medicare drug pricing issues and industry perspectives on whether it was more of a whimper versus a bang. In M&A, the Revance and Crown Laboratories merger was discussed as well as broader M&A trends including how a potential change in the White House could impact the FTC and scrutiny on pharma deals. In...
2024-08-2759 minBiotech HangoutEpisode 112On this week’s Biotech Hangout, hosts Eric Schmidt, Brad Loncar, Brad Skorney, Luba Greenwood and Josh Schimmer kick off the episode summarizing the wild week for biotech stocks. The group also recaps some of the big earning announcements from the week, including a larger discussion on overall learnings from the Q2 earnings season. The hosts discuss Charles River Laboratories as a harbinger of pharma cost cutting and share general perspectives on the IRA impact on pharma. The FDA’s approval of Agios/Servier’s vorasidenib (Voranigo) for glioma was also discussed, with a look back at Servier’s earlier...
2024-08-191h 00Biotech HangoutEpisode 108
On this week’s episode, hosts Chris Garabedian, Brad Loncar, Tim Opler, Dawn Bell, John Maraganore and Eric Schmidt provide a deep dive into the obesity, diabetes and cardiometabolic space, beginning with an overview of the key findings in Stifel’s latest obesity report. The hosts also provide a recap of ADA and EASD abstract highlights and take a look at the next wave of injectable therapies and the trends in consumerization and access. They also discuss Pfizer’s update on its once daily oral GLP-1 pill as well as recent reports on patients discontinuing GLP-1 drugs in two years...
2024-07-231h 00Biotech HangoutEpisode 107On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Tim Opler and Chris Garabedian open up with a conversation on recent trends in M&A for private biotechs versus public companies and the potential impact of the election year. The hosts also cover the important data readouts from the week, including Alnylam’s positive Phase 3 results for its ATTR drug and Lyell’s report of a patient death in its early-stage CAR T trial. Additional data covered includes Wave’s Huntington data readout, Intellia’s redosing of CRISPR gene editing therapy and Savara’s Phase 3 readout in r...
2024-07-021h 02Biotech HangoutEpisode 106On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt, Sam Fazeli, Bruce Booth and Grace Colon discuss the big news of the week including the FDA granting a landmark expanded approval for Sarepta’s Elevidys for patients with Duchenne Muscular Dystrophy. The hosts share their varying opinions on whether the expanded approval was the right decision. The group also engages in a few discussion topics around management, including the “everything is awesome CEO” and the best and worst practices for managing a board. With multiple companies dealing with a stock drop this week (Cabalett...
2024-07-021h 01Biotech HangoutEpisode 105On this week’s Biotech Hangout, hosts Eric Schmidt, Josh Schimmer, Dawn Bell, Brad Loncar, Tim Opler, Sam Fazeli and Paul Matteis kick off the show by discussing CPI data and how inflation is impacting the $XBI, with analysts hopeful that stability will bring lower interest rates soon. The hosts cover the obesity market, providing updates on new datasets, such as findings from $LLY and $NVO, which indicate promising results in liver fat reduction and potential fibrosis reversal with GLP1+ agents. They also discuss competitive dynamics and investor sentiment of the obesity market and highlight the involvement of various play...
2024-06-241h 00Biotech HangoutEpisode 104On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Tim Opler, Eric Schmidt and Sam Fazeli are joined by special guests Jacob Plieth and Madeleine Armstrong for a deep dive into ASCO 2024, including the highs and lows on the data front. The hosts also discuss the shifting interests from pharma companies as some suggest T-cell engagers may have overtaken ADCs and radios in the oncology space. In non-ASCO news, the group covers NASH data from Lilly and Viking and Structure’s data in obesity. The hosts also discuss the latest on BioSecure Act, improving inflation numbers and pick...
2024-06-241h 00Biotech HangoutEpisode 102On this week’s Biotech Hangout, hosts Chris Garabedian, Josh Schimmer, Brad Loncar, Eric Schmidt and Tim Opler kick off the episode with a spotlight on women’s health, which was sparked by Bayer’s Phase 3 data readouts for menopause symptoms. The group also cover Incyte’s $2B share repurchase which leads into a discussion on stock buybacks and the ‘broken’ R&D model. The group also recaps ASGCT 2024 and new gene editing technologies. In deals of the week, the hosts discuss deals and financings from the week, including Takeda and AC Immune’s $100M license agreement, Uniquity Bio’s $300M launch a...
2024-05-281h 01Biotech HangoutEpisode 97On this week’s episode of Biotech Hangout, hosts Brad Loncar, Daphne Zohar, Luba Greenwood and Eric Schmidt kick off the discussion with Vertex’s plans to acquire Alpine Immune Sciences for almost $5 billion in cash, making it the largest deal for the sector in 2024. The hosts also discuss inflation effects on biotech stocks and M&A, macro takeaways from AACR and more fallout from the BioSecurity Act and implications for the industry. The group covers the US Department of Justice’s complaint filed against Regeneron related to its eye drug, Eylea, and the unfortunate impact on the industry’s reputa...
2024-04-161h 01Biotech HangoutEpisode 95On this week’s episode of Biotech Hangout, hosts Brad Loncar, Josh Schimmer, Grace Colon, Chris Garabedian, and Eric Schmidt discuss the latest biotech industry news including M&A, regulatory news, pricing strategies, and progress within women’s health and neurological disorders. The hosts cover data from Roche’s IL-6 program, Biohaven’s degrader program, followed by Crinetics’ Phase 3 data in acromegaly. On the M&A front, the hosts discuss AstraZeneca’s acquisition of Fusion Pharmaceuticals. The group also talks through Orchard Therapeutics’ breakthrough $4.25 million drug, and the impact of high drug prices on the industry as a whole. They also weigh in on t...
2024-03-271h 01Biotech HangoutEpisode 94On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Tim Opler, Michal Preminger, Eric Schmidt and Yaron Werber discuss the latest biotech news, including commentary on the biotech sector performance in 2024 and a pharma R&D investment overview. The hosts cover the week’s notable M&A, including AstraZeneca’s acquisition of Amolyt plus Novartis’ acquisition of IFM Due and a related discussion on option-to-buy deals. The group also discusses Ionis meeting the primary endpoint in its Phase 2 MASH trial and Madrigal’s historic accelerated approval for NASH/MASH. Other topics include Eli Lilly’s partnership...
2024-03-271h 01Biotech HangoutEpisode 93On this week’s episode of Biotech Hangout, hosts Brad Loncar, Daphne Zohar, Tim Opler, Brian Skorney, Luba Greenwood and Yaron Werber discuss the latest biotech news, including the delay of Eli Lilly’s Alzheimer’s drug donanemab as the FDA requires an AdComm and Amylyx’s ALS Phase 3 trial failure that caused the stock to drop 80%. The hosts also weigh in on how the 2024 presidential election will impact biopharma and takeaways from the 2024 Cowen conference, including the number of generalist investors in attendance and how obesity has become a dominant narrative in the industry. The group also discusses the Boun...
2024-03-201h 03Biotech HangoutEpisode 91On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Eric Schmidt and Yaron Werber discuss the latest biotech news, including the IPO window creaking back open and aftermarket performance up 12-19% for secondary offerings and IPOs. The hosts also discuss the FTC challenges facing industry M&A and another roadblock for AbbVie’s Cerevel deal. The retirement of AbbVie CEO Richard Gonzalez prompts a discussion amongst the hosts on important qualities of a CEO. A range of FDA-related news from the week is also covered including the approval of Iovance’s Amtagvi as first T-cell therap...
2024-03-201h 04Biotech HangoutEpisode 87On this week’s Biotech Hangout, hosts Brad Loncar, Tim Opler, Luba Greenwood and Brian Skorney discuss the latest industry news including 2 biotech IPOs from ArriVent Bio ($175M) and CG Oncology ($380M). They also discuss Sanofi buying Inhibrx ($2.2B), Kura Oncology’s private placement ($150M) and Gilead’s failed phase 3 study. The hosts cover class-wide black box warnings from the FDA, including Amgen’s Prolia, plus Eli Lilly’s investigational gene therapy for hearing loss data, HPV vaccine study in Scotland and The House Ways and Means Committee approves restoration of R&D tax credit. *This episode aired on January 26
2024-02-0258 minBiotech HangoutEpisode 86This week, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, John Maraganore and Grace Colon discuss the news of the week including several early-stage IPO filings that kicked off the year: Kyverna Therapeutics, CG Oncology and Alto Neuroscience. The hosts also cover AI enabled biomarkers following the FDA’s clearance of two AI diagnostic tools, plus the FDA expands approval of Vertex and CRISPR’s Cagevy as a first CRISPR-edited therapy for beta-thalassemia. They also discuss early-stage funding and an amicus brief that many biotech executives have signed, following the decision on Mifepristone. Other topics include BridgeBio Pharma securing capital from...
2024-01-251h 02Biotech HangoutEpisode 85On this week’s Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Brad Loncar, Dawn Bell and Sam Fazeli discuss the latest in biotech news, including their takeaways from last week’s JPM 2024 conference and Brad’s BiotechTV interviews with several attendees. The hosts also discuss the many deals from the week including Merck’s acquisition of Harpoon Therapeutics ($680M), Johnson & Johnson’s acquisition of Ambrx ($2B), GSK acquires Aiolos Bio ($1.4B), Boston Scientific acquires Axonics ($3.7B) and several Novartis deals including their dropped pursuit of Cytokinetics, acquisition of Calypso ($250M), their licensed drugs from a China biotech ($185M) and their deal...
2024-01-181h 00Biotech HangoutEpisode 83Guest host Nick Shipley, Bio’s policy expert joins Daphne Zohar, Brad Loncar, Mike Yee and Yaron Werber on this week’s Biotech Hangout. The group discusses policy affecting biotech, including march-in rights, PBMs, IRA and FTC involvement plus bipartisan initiatives like the Orphan Cures Act. They also discuss the state of the XBI and industry sentiment, Bluebird Bio’s setbacks following FDA approval and Pfizer’s stock after its 2024 forecast revenue. They cover data from Vertex, Icosavax, Arcellx and Legend, plus several ADC deals including Bristol Meyers Squibb, SystImmune, C4 Therapeutics, Merck, Nona Biosciences and Pfizer. Other topics include...
2024-01-101h 09Biotech HangoutEpisode 80Hosts Brad Loncar, Tim Opler, Josh Schimmer, Dawn Bell and Yaron Werber discuss the latest industry news on this week’s episode of Biotech Hangout. They cover several upcoming conferences including the American Heart Association, which the hosts say will highlight market moving data and a “biologics revolution”, plus ACR, which will highlight CAR-T data, and the Liver Meeting. The hosts also discuss Eli Lilly’s drug approval for weight management, Cargo Therapeutics’ IPO terms and Adverum’s 3-year AMD data. There is also news in the I&I space from Moonlake Therapeutics, who was off by more than 20% after announ...
2023-11-201h 02Biotech HangoutEpisode 78Guest host Paul Matteis, Biotech Analyst at Stifel, joins Daphne Zohar, Brad Loncar, Josh Schimmer, Dawn Bell and Bruce Booth on this week’s episode of Biotech Hangout to discuss market sentiment, biotech’s bear market, CTAD and World Sleep meetings and Roche to acquire Telavant ($7.1B). The hosts also cover industry issues such as the Orphan Cures Act, More Transparency Act, PRVs and more after Daphne attended meetings with senators and congressmen in DC. Additionally, they talk about the second largest A round of funding in 2023 from Aiolos Bio ($245M) plus OrbiMed’s $4.3B raise, CARGO Therapeutics’ IPO and >40...
2023-11-021h 01Biotech HangoutEpisode 76On Biotech Hangout this week, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Mike Yee & Tim Opler discuss biotech sentiment & cover the big news of the week. M&A as a topic including Bristol Myers Squibb to acquire Mirati Therapeutics for $4.8B, plus the 14 biotech acquisitions in 2023 over $1B and Illumina ordered to sell Grail after completing a $7.1B acquisition deal. A lot of data came out this week from companies including Akero, Alnylam, Ventyx, Merck, Novo Nordisk, Immunic and PMV Pharmaceuticals. Mike and Brad also share takeaways from Jefferies CNS Day and HLTH 2023. *This episode aired on October 13, 2023*
2023-10-1659 minBiotech HangoutEpisode 75On this week’s Biotech Hangout, hosts Brad Loncar, Daphne Zohar, Bruce Booth, Josh Schimmer and Yaron Werber cover the state of the XBI after it hit a 52-week low. They also discuss several deals and financings from the week including Eli Lilly acquiring Point Biopharma ($1.4B) and radiopharma more generally and Sanofi paying Teva to collaborate on inflammatory bowel disease treatment (up to $1.5B). Also Biohaven’s offering (~$225M), Amicus Therapeutics’ financing with Blackstone ($430M), and Orchard Therapeutics acquired by Kyowa Kirin ($478M). Takeda announces withdrawal of EXKIVITY after its accelerated approval gets pulled, Syndax, ALX Oncology and Roche data an...
2023-10-161h 04Biotech HangoutEpisode 73Josh Schimmer returns on this week’s Biotech Hangout and joins hosts Brad Loncar, Tim Opler, Dawn Bell and Brian Skorney to discuss the industry news of the week. They cover the state of the XBI, IPOs and M&A, plus the ORPHAN Cures Act and low demand for biotech lab space. The hosts also discuss several Phase 3 results from the week (Travere, Iveric, AstraZeneca/ Daiichi Sankyo & Seagen), and partnerships given back to companies (Chiesi gives rights back to Inhibrx & Novartis gives rights back to BeiGene). Other topics include ARS Pharma’s CRL from the FDA, Fresh Tracks returning cash...
2023-10-031h 00Biotech HangoutEpisode 72Guest Yaron Werber joins hosts Daphne Zohar, Chris Garabedian and Brad Loncar for this week’s Biotech Hangout, centered on the theme of ‘management and culture.’ They cover the big IPO news of the week from Neumora (~$2.5B valuation) and RayzeBio (~$1B valuation) plus Acelyrin’s share value drops after sharing top-line results despite being the largest biotech IPO this year. They also discuss Goldman Sachs dropping its price targets and ratings for “early-stage” biotechs and updates from both Moderna and Roche, who held their R&D days this week. Also, Galapagos’ 52-week low and the contrast with Argenx plus the FDA a...
2023-09-221h 00Biotech HangoutEpisode 70On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Tim Opler, Brad Loncar, Brian Skorney and Michal Preminger discuss the latest industry news including how the state of biotech M&A is tracking and the potential impact of the FTC’s two new proposed rules – plus the latest on Amgen and Horizon’s FTC lawsuit. The hosts also cover private equity financings, including Taysha Gene Therapies’ PIPE and the background behind Biogen’s bid to acquire Reata. Additional coverage includes data and regulatory updates (Seagen, Pfizer, Delcath, Galecto, 2seventy bio) as well as how the FDA weighs mixed data a...
2023-08-2955 minBiotech HangoutEpisode 69On Biotech Hangout this week, Brad Loncar, Chris Garabedian, Sam Fazeli, Rob Perez and Ethan Perlstein discuss the influence of GLP-1s including cost, safety, drawbacks and more in light of Novo Nordisk’s positive semaglutide SELECT study results and Eli Lilly’s earnings, which rose due to their type 2 diabetes drug. Other big topics include last week’s Sage and Biogen news following the FDA’s decision to approve zuranolone for PPD but not MDD and its effect on Sage’s stock, plus progress and setbacks in ultra rare diseases including Taysha Gene Therapies. The hosts also dive into Iveri...
2023-08-1759 minBiotech HangoutEpisode 68On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Tim Opler, Brad Loncar, Bruce Booth, Otello Stampacchia and Mike Yee cover industry news from the week. They discuss the latest deals including Alexion acquiring Pfizer’s rare disease gene therapy portfolio and Revolution Medicines acquisition of EQRx and a broader discussion of merging with negative EV companies as a strategy for fundraising and the “fundability” of certain founders. The hosts also dive into the hot topic of the week: Biogen and Sage’s PDUFA for zuranolone in MDD and PPD. Additionally, they cover the busy week of Q2 earning...
2023-08-091h 00Biotech HangoutEpisode 67On this week’s episode of Biotech Hangout, guest Matthew Gline (CEO of Roivant) joins hosts Brad Loncar, Tim Opler and Brian Skorney to discuss Biogen’s heavy news week, including their acquisition of Reata for $6.5 billion, their decision to cut 1,000 jobs by 2025 and their quiet stance regarding their upcoming PDUFA date to treat PPD and MDD in partnership with Sage. The hosts also cover other layoff and leadership changes, including the resignation of FibroGen’s CEO and layoffs from Infinity and Mersana. The group also touches on the $2.8 billion hypertension deal between Roche and Alnylam and the impact this d...
2023-08-011h 00Biotech HangoutEpisode 66On this week’s episode of Biotech Hangout, guest Neil Kumar (CEO of BridgeBio) joins hosts Daphne Zohar, Brad Loncar, Tim Opler, Bruce Booth and Brian Skorney to discuss BridgeBio’s long awaited, positive Phase 3 transthyretin amyloid cardiomyopathy (ATTR-CM) data, including the company’s ups and downs and some leadership lessons along with the benefits of diversification. The hosts also cover the Acumen Pharmaceuticals and Eli Lilly positive Alzheimer’s data, in addition to questions around safety for eye disease trials related to Apellis’ Syfovre and Horizon Therapeutics’ Tepezza. With a news heavy week, the group also discusses data integrity is...
2023-08-0159 minBiotech HangoutEpisode 65On this week’s episode of Biotech Hangout, hosts Brad Loncar, Chris Garabedian, Tim Opler, Dawn Bell and guest host Brian Skorney talk the latest in industry news. They discuss the first FDA approved Alzheimer’s drug to slow cognitive decline plus the subsequent retirement of Esai’s CEO /Alzheimer’s lead. Several other headlines this week including Eli Lilly’s Versanis acquisition, ADC Therapeutics pausing trial enrollment, Illumina’s fine and BeiGene and Novartis terminating their agreement. The hosts also talk about China-related news including the FDA planning to import more doses of chemotherapy from China and four of the top 1...
2023-07-2059 minBiotech HangoutEpisode 63This week, hosts Daphne Zohar, Brad Loncar, Tim Opler & Michal Preminger focus on the theme of people and reputation in the industry. The hosts (and several audience members, including STAT reporter Allison DeAngelis and Kojin Therapeutics CEO Luba Greenwood) discuss the hot topic of the week - media coverage of Biogen board changes. Additionally, in the wake of Ram Sasisekharan speaking out after a four-year investigation exonerated him, the group discusses repercussions for accusers and impact to reputation. In addition to people topics, the hosts cover the week’s financings and M&A including the first biotech to file fo...
2023-06-231h 03Biotech HangoutEpisode 62This week, Daphne Zohar, Brad Loncar and John Maraganore hosted a special live edition of Biotech Hangout at the BIO conference, and they dive into their learnings on this week’s episode. They are also joined by Josh Schimmer and Otello Stampacchia to discuss the latest news, data, deals and more. The hosts debate the hot topic of the week - Merck’s lawsuit against the U.S. government’s IRA negotiations. They also discuss data that was shared at the recent ASCO 2023 conference, and a tweet accused of moving stock. Other topics include a surprising acquisition and oncology respon...
2023-06-1458 minBiotech HangoutEpisode 61On Biotech Hangout this week, hosts Daphne Zohar, Josh Schimmer, Tim Opler, Chris Garabedian and Brad Loncar talk the latest biotech news. Several of the hosts report live from ASCO 2023 and share highlights and headlines from the conference as well as general industry sentiment around oncology companies. The hosts also discuss the latest deals and financings and debate short-sellers and activist investors and their effect on biotech stocks. Other topics include data from Sanofi, Icosavax, Pfizer and BioHaven over the last two weeks, the FDA’s decision on Sarepta, perspectives on accelerated approvals for rare disease, Amylyx’s ALS drug...
2023-06-0658 minBiotech HangoutEpisode 60On this week’s Biotech Hangout, hosts Daphne Zohar, Mike Yee, Otello Stampacchia, Brad Loncar and Bruce Booth discuss the latest in the biopharma industry including public offerings, deals and financings, data and more. The group dives into the slowdowns in private financings, whether or not the IPO window should be open by now, and the Akero and Coherus follow-on offerings. There is a debate as to whether the news that the FTC is suing to block Amgen from acquiring Horizon Therapeutics has positive or negative effects on SMID cap biotechs. The group also discusses the FTC’s widening prob...
2023-05-2458 minBiotech HangoutEpisode 57On this week’s episode of Biotech Hangout, CEO of Bellus Health (announced this week that GSK is acquiring for $2B), Roberto Bellini, joins hosts Daphne Zohar, Tim Opler, Dawn Bell, Sam Fazeli and Brad Loncar. The group discusses the week’s deals and financings, data and broader themes of innovation. Roberto shares his personal experience going through an acquisition and what it took for his company to get to that point from a TSK listed microcap valued at ~$15M to a $2B success story, his thoughts on innovation taking many different forms and the pros and cons of sing...
2023-04-251h 00
All-In with Collin (Poker)Jon Pardy, BetOnDrew and Michael Loncar talk poker, sports, Thirst Lounge and more!Shoutouts 0:01:10
Chat with Jon Pardy about all things hockey, Big Brother, Thirst Lounge and ACR at 2:07
Tournament of the week 29:32
Catching up with BetOnDrew about Costa Rica, Thirst Lounge, ACR, Food, Street poker, Live stream 30:28
I speak with Michael Loncar about how his dad introduced him to poker, twitter ban, ACR, 100K contest and more 1:03:13
Follow Jon Pardy https://twitter.com/jon_pardy
Follow BetOnDrew https://twitter.com/BetOnDrew
Follow Michael Loncar https://instagram.com/michael_loncar
Follow me https://twitter.com/PokerCapone
---
Send in a voice message: https://podcasters.spotify.com/pod/show/allinwithcollin/message
2023-04-231h 35Biotech HangoutEpisode 56On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Tim Opler, Michal Preminger and Brad Loncar discuss the latest industry news including deals and financings, data, regulatory and more. Brad starts the episode by sharing a personal update on the health of his father, thanking the biotwitter community and lauding the first responders, nurses and specialists who helped save him. Despite some industry setbacks from the week, there was positive news to share including data from a Torreya study, which showed the specialist buyside remained strong at the end of 2022 as well as a list of...
2023-04-181h 03Biotech HangoutEpisode 51On Biotech Hangout this week, hosts Daphne Zohar, Josh Schimmer and Brad Loncar are joined by Andy Plump, President, Research & Development at Takeda, and Mathai Mammen, former Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson. The group kicks off with a discussion on productivity in the pharma industry, including cost increases to the innovations that are on the horizon and improved efficiencies in trials, manufacturing and beyond. The group transitions to talk about the latest industry news, regulatory actions and notable recent fundings. They examine the scrutiny around the recent FDA approval of Reata’s treatment for a rare ne...
2023-03-131h 06Biotech HangoutEpisode 44On the two-year anniversary of the launch of Biotech Hangout (formerly Biotech Clubhouse), Daphne and Josh are joined by Chris Garabedian and Brad Loncar, two of the Biotech Clubhouse co-founders, and Bruce Booth, Dawn Bell & Michal Preminger all drop in. The group kicks off the episode with outlook on 2023 and an in-depth recap of the J.P. Morgan 2023 Healthcare Conference. Overall themes include the “Monday Mystique” of industry pressure to announce deals at the start of the conference, Brad’s successful video series full of conversations with notable biopharma CEOs, diversity & inclusion, and an emerging globalization theme. Hosts also cover M&A...
2023-01-191h 00Biotech HangoutEpisode 43On the first Biotech Hangout episode of 2023, Daphne, Josh, and Tim are joined by Jefferies’ biotech analyst Michael Yee to recap the deals, financings, and clinical readouts that stood out in 2022. The group discusses the upcoming annual J.P. Morgan Healthcare conference and makes future predictions for 2023, including a possible rebound in China and amore obesity, CNS and small molecule deals. They discuss the Inflation Reduction Act and dive into Jefferies’ January XBI heat map. The group recaps Brad Loncar’s 2023 predictions in Business Insider and discuss what investors will want to see more of this year. They also make p...
2023-01-1155 minBiotech HangoutEpisode 41Hosts Daphne, Josh, Tim and Otello are joined by special guest and biotech investor, Brad Loncar, to discuss the current M&A landscape, data announcements from the week and recent FDA and regulatory movements. Otello began the episode with his observations of trends in M&A including speedy execution of deals and lack of competition to get them. Daphne goes into detail about this week’s deals, including a new, high-stakes partnership between Summit Therapeutics and Akeso to in-license a bispecific antibody, a deal that could be worth up to $5 billion. Brad reflects on the popularity of cell therapies in...
2022-12-1658 minBiotech HangoutEpisode 32Paul Rennert, CEO, President and CSO of Aleta Biotherapeutics joins hosts Daphne Zohar, Brad Loncar and Chris Garabedian to discuss access to research and journal publications. Original air date: August 28, 2022.
2022-10-051h 15
Too Posh PodcastGrace Caroline Loncar May 7, 2000 - November 26, 2016 "I hold you in my heart until I can hold you again in Heaven" Sue LoncarWe continue with part 2 of the brave Sue Loncar ........ In this episode we learn all about who Grace Caroline Loncar was, the gifts she has and the purpose and legacy in her name. "This little girl has a purpose - I am going to name her Grace" Sue Loncar said when she found out that she was pregnant with her. She says the only way for her to survive Grace's death is to believe that she has not lost Grace and that she is still her mother and will be reunited with her. She feels that Grace is...
2022-08-3124 min
Behind BiotechSeason 2| China: Brad Loncar on Investment Risk and Innovation Drivers in Chinese BiotechBrad Loncar Biography
Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. He’s also the co-host of Biotech Clubhouse, which recaps the week’s biot...
2022-04-1452 minToo Posh PodcastBEST OF TOO POSH: "Hold Tight To The Memories For Comfort" In Memory of Brian and Grace Loncar- Sue Loncar shares her memories of the beginnSeptember is Suicide Prevention Month and the brave Sue Loncar joins us to share her story. Her mission is to destroy the stigma and help at least one person and show them they are not alone in their journey and struggles. Sue's precious daughter Grace Loncar committed suicide at age 16, almost 4 years ago and her Dad Brian Loncar, a prominent Texas personal injury lawyer "The Texas Strong Arm"passed away 2 days after his daughter's funeral from an accidental drug overdose. They say that he died of a broken heart. The pain and suffering Sue is...
2022-02-1025 min
Opto Sessions – Invest in the Next Big IdeaBrad Loncar - Investing in Biotech, Chinese Biopharma & The Immunocology ETFBrad Loncar is a Biotechnology expert, a pioneer in Biotech investment, and the index provider for two Nasdaq-listed biotech ETFs, Loncar’s Cancer Immunotherapy ETF, and the China BioPharma ETF. Brad is CEO of Loncar Investments and has a wealth of investment experience, having started out at Franklin Templeton as part of their Management Training Program. Brad’s also spent time in the US political sphere, having been appointed Senior Advisor at the U.S. Department of the Treasury, in between an Investment Directorship in the Bush-Cheney administration in 2004, and a short tenure as Director of Administration for J...
2021-07-011h 16
ChairChair ep.18 - Branislav Loncar - Future of advertising - Marcel is hereToday huge innovation, that big that completely changed the business model, and as it goes the whole industry. To have even bigger significance, an industry that is entrenched in its own success for the last 115 years - advertising!On this subject we talk with Branislav Loncar, CFO of Publicis Groupe SEE.Branislav specializes in evaluation of investments, audit and accounting. But there is much more about him than it meets the eye.Bane is the youngest CFOs that Publicis Groupe ever head, and for a few years now, Southeast Europe...
2021-04-0825 min
Restarting AmericaBreaking into the Hemp Industry during a Pandemic: Cannabis Advocate Maryann LoncarIn this episode of Restarting America, Josh Gibbs from 97 Switch interviews Maryann Loncar, a cannabis advocate who has helped craft legislation in Illinois for the last 15 years. Throughout the interview, they discuss the impacts of the COVID-19 pandemic on business and society. Loncar shares how the current health pandemic has affected her work and how she is adapting to new circumstances.
Loncar co-wrote the first Illinois Industrial Hemp bill SB1294. She also helped secure the passing of the current hemp bill SB2298 and co-wrote the current Medical Cannabis Pilot Program in Illinois. Loncar worked on both sides...
2021-02-0425 min
Understanding Projects#7 - John Loncar: Project stakeholder managementThis episode features John Loncar who discusses the importance of stakeholder management. John is a profession engineer (P. Eng) and holds Masters degrees in both engineering and business administration. His career experience has lent itself towards engineering problem solving, internal and external customer sales & service, capital budgeting and reconciliation, and management of staff. He current works in the energy industry and has held leadership roles as a District Engineer, a Utility Service Manager in Distribution Operations, and as a senior Advisor in Commercial/Industrial Sales and Marketing.
For more information about John: https://www.linkedin.com/in/john-loncar...
2021-01-2327 min
Escape To The Soul-Stirring Full Audiobook Experience!Greek Philosophy 101: Surprising Insights from Ancient Wisdom by Samuel LoncarPlease visithttps://thebookvoice.com/podcasts/1/audiobook/488368to listen full audiobooks.
Title: Greek Philosophy 101: Surprising Insights from Ancient Wisdom
Author: Samuel Loncar
Narrator: Samuel Loncar
Format: Unabridged Audiobook
Length: 6 hours 41 minutes
Release date: November 19, 2020
Ratings: Ratings of Book: 3.87 of Total 67
Ratings of Narrator: 3.67 of Total 3
Genres: Ancient Civilizations
Publisher's Summary:
Born in Athens, Greece, acclaimed Yale-educated philosopher Samuel Loncar helps you discover how ancient Greek philosophy-or "love of wisdom"-forms powerful bridges between East and West as well as past and present. In this provocative audio course, you will explore Greek philosophy in its historical context, in which philosophy was not...
2020-11-196h 41Experience Into A Ground-Breaking Full Audiobook While Cooking.Greek Philosophy 101: Surprising Insights from Ancient Wisdom by Samuel LoncarPlease visithttps://thebookvoice.com/podcasts/1/audiobook/488368to listen full audiobooks.
Title: Greek Philosophy 101: Surprising Insights from Ancient Wisdom
Author: Samuel Loncar
Narrator: Samuel Loncar
Format: Unabridged Audiobook
Length: 6 hours 41 minutes
Release date: November 19, 2020
Ratings: Ratings of Book: 3.87 of Total 67
Ratings of Narrator: 3.67 of Total 3
Genres: Lessons in Philosophy
Publisher's Summary:
Born in Athens, Greece, acclaimed Yale-educated philosopher Samuel Loncar helps you discover how ancient Greek philosophy-or "love of wisdom"-forms powerful bridges between East and West as well as past and present. In this provocative audio course, you will explore Greek philosophy in its historical context, in which philosophy was...
2020-11-196h 41Get New Full Audiobooks in History, Ancient CivilizationsGreek Philosophy 101: Surprising Insights from Ancient Wisdom by Samuel LoncarPlease visithttps://thebookvoice.com/podcasts/1/audiobook/488368to listen full audiobooks.
Title: Greek Philosophy 101: Surprising Insights from Ancient Wisdom
Author: Samuel Loncar
Narrator: Samuel Loncar
Format: Unabridged Audiobook
Length: 6 hours 41 minutes
Release date: November 19, 2020
Ratings: Ratings of Book: 3.87 of Total 67
Ratings of Narrator: 3.67 of Total 3
Genres: Ancient Civilizations
Publisher's Summary:
Born in Athens, Greece, acclaimed Yale-educated philosopher Samuel Loncar helps you discover how ancient Greek philosophy-or "love of wisdom"-forms powerful bridges between East and West as well as past and present. In this provocative audio course, you will explore Greek philosophy in its historical context, in which philosophy was not...
2020-11-196h 41
Get New Full Audiobooks in History, Ancient CivilizationsGreek Philosophy 101: Surprising Insights from Ancient Wisdom by Samuel LoncarPlease visit https://thebookvoice.com/podcasts/1/audiobook/488368 to listen full audiobooks. Title: Greek Philosophy 101: Surprising Insights from Ancient Wisdom Author: Samuel Loncar Narrator: Samuel Loncar Format: Unabridged Audiobook Length: 6 hours 41 minutes Release date: November 19, 2020 Ratings: Ratings of Book: 3.87 of Total 67 Ratings of Narrator: 3.67 of Total 3 Genres: Ancient Civilizations Publisher's Summary: Born in Athens, Greece, acclaimed Yale-educated philosopher Samuel Loncar helps you discover how ancient Greek philosophy-or "love of wisdom"-forms powerful bridges between East and West as well as past and present. In this provocative audio course, you will explore Greek philosophy in its historical context, in which philosophy was...
2020-11-1905 minToo Posh Podcast#212: "Live with Grace" $10.000 Scholarship to a Booker T Senior in honor of Grace LoncarWhen Sue Loncar was in total despair, after the death of her 16 year old daughter and her husband within days of each other she felt hopeless with no ideawhat to do next. Her best friend of many years Libby, told her she was going to run the "Grace Loncar Foundation", which she started immediately, filed all the paperworkand they had their first meeting 2 weeks after Grace was gone. www.graceloncarfoundation.comA big reason for the foundation is to end the stigma because people do not want to talk about it. Suicide has...
2020-10-2055 minToo Posh Podcast#210: Grace Caroline Loncar May 7, 2000 - November 26, 2016 "I hold you in my heart until I can hold you again in Heaven" Sue LoncarWe continue with part 2 of the brave Sue Loncar ........ In this episode we learn all about who Grace Caroline Loncar was, the gifts she has and the purpose and legacy in her name. "This little girl has a purpose - I am going to name her Grace" Sue Loncar said when she found out that she was pregnant with her. She says the only way for her to survive Grace's death is to believe that she has not lost Grace and that she is still her mother and will be reunited with her. She feels that Grace is...
2020-10-0624 minToo Posh Podcast#209: "Hold Tight To The Memories For Comfort" In Memory of Brian and Grace Loncar- Sue Loncar shares her memories of the beginning before tSeptember is Suicide Prevention Month and the brave Sue Loncar joins us to share her story. Her mission is to destroy the stigma and help at least one person and show them they are not alone in their journey and struggles. Sue's precious daughter Grace Loncar committed suicide at age 16, almost 4 years ago and her Dad Brian Loncar, a prominent Texas personal injury lawyer "The Texas Strong Arm"passed away 2 days after his daughter's funeral from an accidental drug overdose. They say that he died of a broken heart. The pain and suffering Sue is...
2020-09-2925 min
Beyond the FieldWhat is AML featuring Akash Khushal & Nina Bly-Pieterson from One AML Audit | Ep. 122Anti Money Laundering (AML) and Combatting the Financing of Terrorism (CFT) eekk! That sounds a bit scary – but we promise it’s not. Hosts Goran Loncar and Isa Nacewa sit down with industry experts Akash Khushal & Nina Bly-Pieterson from One AML Audit to explain everything there is to know about AML and CFT. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follo...
2020-08-3117 minBeyond the FieldSpending Habits from the Nationwide Lockdown. | Ep. 116During the nationwide lockdown in March and April 2020, household spending statistically changed! Because we couldn't spend, there was an increase of savings, and in turn, people were able to pay off consumer debts! Kayne zooms with Money Empire Senior Adviser Goran Loncar to talk about the change in spending habits and how it resulted in $1.3b worth of consumer debt being repaid. Imagine the result if we maintained some of those reduced spending habits! Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questi...
2020-08-2407 minBeyond the FieldMONEY WEEK SPECIAL - Savings. | Ep. 109Money Week Special - BTF talk with Goran Loncar, Money Empire Senior Adviser on the different types of savings, why it's so important to create an emergency fund and how Kiwisaver acts a compulsory savings account.Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice shared on Beyond t...
2020-08-1207 minBeyond the FieldMONEY WEEK SPECIAL - Expenses. | Ep. 107Money Week Special - BTF talk with Goran Loncar, Money Empire's Senior Adviser on what the three types of Expenses are being fixed, variable & discretionary. We also share tips to reduce your outgoings and things to be aware of. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice sh...
2020-08-1006 minBeyond the FieldHow to Use KiwSaver to Buy your First Home | Ep. 85If you’ve been a member of KiwiSaver for more than three years you may need to be able to use part of your balance to purchase your first home. This chunk of cash may be what you need to get a leg up onto the property ladder but there are a few hoops you need to jump through before you can use it. Kayne and Isa are joined by Money Empire Senior Adviser Goran Loncar to chat at things KiwiSaver. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podc...
2020-06-2204 minBeyond the FieldHow to take advantage of the All Time Low Interest Rates | Ep. 68"I'm currently fixed - what do I do?""I want to lock in a lower rate - how do I do that?""Do I need to refinance to be able to get access to these low rates?" These are just some of the questions we have been receiving lately from our clients. The BTF team is joined by Goran Loncar to help explain your options when it comes to taking advantage of these super-low rates. We cover the steps you need to take and how to determine if it's beneficial to break your current fixed m...
2020-05-2504 minBeyond the FieldIncome Lending Criteria - May Summary | Ep. 63The BTF team discuss with Goran Loncar ME adviser, what the banks need for income verification for those employed vs self-employed. COVID is creating havoc and lending space is no different - listen in for some tips. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice shared on Beyond...
2020-05-1309 min
Beyond the FieldCOVID-19 LOCKDOWN. DAY 26. The Team Behind the Mic – Goran Loncar | Ep. 49Get to know the team behind the mic. We are lucky enough to have a talented team of experts who regularly appear on our Beyond the Field series. Money Empire has a diverse team with a range of different backgrounds and experience. Today, Isa talks with inhouse self-proclaimed funny man and lending expert Goran Loncar. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https...
2020-04-1906 minBeyond the FieldCOVID-19 LOCK DOWN – DAY 7. Budgeting Basics| Ep. 37Kayne is joined again by Goran Loncar to explain budgeting. Whilst we hear about budgeting all the time, it’s an underestimated power tool. The BTF team discuss the perks to spend the time to set a budget and how small changes can have lasting benefits.Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebo...
2020-03-3106 min
Becoming HumanEp. 3: Jesus the Philosopher? A Jewish RevolutionNo single person has shaped history more than an obscure Jewish teacher who was executed by the Roman empire. Today, we know him as a god, a myth, a savior. In fact, he was the greatest philosopher of his time: Jesus of Nazareth. Becoming Human: Origins Samuel Loncar, Ph.D. (Yale)
2020-03-3142 minBeyond the FieldWhy do people refinance? | Ep. 31We have Money Empire’s inhouse lending expert Goran Loncar filling in for Isa Nacewa to discuss refinancing, why people do it and the benefits involved. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice shared on Beyond the Field is general in nature and does not consider yo...
2020-03-2406 min
Becoming HumanEp.2: The Myth of Secular Philosophy: Socrates as a Religious MartyrSocrates is perhaps our most famous philosopher. But his life and death defy our dominant ideas of reason and religion. By paying the ultimate price for his philosophy, Socrates became the West's first great religious martyr, changing his world, and ours. Becoming Human: Origins Samuel Loncar, Ph.D. (Yale)
2020-03-2151 min
Becoming HumanEp. 1: Religious Atheists: Philosophy's Untold StoryThis episode exposes modern myths about philosophy, religion, and science. To see the truth about ourselves and our culture, we need to recognize Socrates for who he really was: a religious revolutionary. Becoming Human: Origins Samuel Loncar, Ph.D. (Yale)
2020-03-1140 minBeyond the FieldWhy it’s important to insure you! | Ep. 23In this episode, Kayne & Isa chat with Goral Loncar from Money Empire on why you are your biggest asset in life and not the property you own.Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice shared on Beyond the Field is general in nature and does not cons...
2020-03-0305 minBeyond the FieldHouse Insurance | Ep. 22In this episode, Kayne & Isa chat with Goral Loncar from Money Empire on the importance of house insurance and a basic overview of the terms. Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice shared on Beyond the Field is general in nature and does not consi...
2020-03-0107 minBeyond the FieldExpert Commentary on Why Banks Decline Mortgages with Goran Loncar | Ep. 10In this episode Kayne & Isa speak to Senior Adviser Goran Loncar from Money Empire where he talks about reasons why a bank may decline your mortgage application. He touches on bank statements, transactions, account conduct, credit cards and income.Thank you to our series sponsor – Atomic Coffee. These legends fuel us and our guests through our podcasts. If you have any questions or comments, or have a topic you want us to discuss you can contact us at https://moneyempire.co.nz/, or follow us on Facebook https://www.facebook.com/MoneyEmpireNZ/ The advice s...
2020-02-0311 min
Asia Healthcare Podcast#001 - Brad Loncar, CEO of Loncar InvestmentsIn this first episode, I sat down with Brad Loncar to talk about the China biotech sector and more:
- How did Brad get into biotech investing?
- What are the differences between the U.S. and China biotech sector? How will HKEx and Shanghai's tech board reshape the IPO market?
- How will China's drug pricing reforms impact global drug prices?
- What is the 4+7 procurement pilot program? Are Chinese pharmas shifting towards innovation?
- How will the ongoing trade war impact the industry? What is Brad's long...
2019-04-0844 min